

Mandos Health

U.S. Expanded Access Program to Continue, September 17, 2021

To The NPC1 Community,

We are thrilled today to announce that we've reached agreement with the FDA to officially continue the US Expanded Access Program (EAP) for intrathecal and/or intravenous administration of adrabetadex* beyond October 20th, 2021.

We recognize the anxiety, concern, and frustration caused by the uncertainty related to this program prior to our acquisition of adrabetadex and we hope that this announcement will reduce at least some of the tension that patients, caregivers, families, and physicians have been experiencing for the past nine months.

We still have much work to do and will be in touch again soon with further updates.

Sincerely,

Scott Riccio
EVP, Patient & Community Engagement
Mandos, LLC
www.mandoshealth.com

**Adrabetadex is an investigational drug that has not been approved by FDA, and FDA has not found it to be safe and effective for use to treat NPC1 or for any other use.*

Mandos Health

A world of support for all affected by NPC1

Research. Access. Collaboration.

#NoStoneLeftUnturned #TheRightThingToDo #BuiltForPatients